Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy
Brief Summary: The purpose of this study is to assess the safety and efficacy of omarigliptin compared to placebo in participants with inadequate glycemic control on metformin monotherapy. The primary hypothesis is that after 24 weeks, the addition of treatment with omarigliptin provides greater reduction in hemoglobin A1c (A1C) than placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin, Drug: open-label metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glimepiride, Drug: open-label metformin | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: glimepiride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: open-label metformin; Assigned to Arm(s): 1, 2
B: Arm Label: Placebo/Sitagliptin; Type: OTHER; Interventions: Drug: Placebo, Drug: Sitagliptin, Drug: Metformin, Drug: Pioglitazone | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Pioglitazone | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin
C: Arm Label: linagliptin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin 5 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Omarigliptin (Phase A) → Omarigliptin (Phase B); Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin, Drug: Matching placebo to glimepiride, Drug: Insulin glargine, Drug: Metformin | Arm Label: Placebo to omarigliptin (Phase A) → Glimepiride (Phase B); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to omarigliptin, Drug: Glimepiride, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B) | Intervention Type: DRUG; Name: Matching placebo to omarigliptin; Assigned to Arm(s): Placebo to omarigliptin (Phase A) → Glimepiride (Phase B) | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Placebo to omarigliptin (Phase A) → Glimepiride (Phase B) | Intervention Type: DRUG; Name: Matching placebo to glimepiride; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B) | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B), Placebo to omarigliptin (Phase A) → Glimepiride (Phase B) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Omarigliptin (Phase A) → Omarigliptin (Phase B), Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)

Answer: D